Disclosed positions
| DENALI THERAPEUTICS INC | DNLI | COM | $49,144,027 | 1,910,732 | SH | None |
| SANA BIOTECHNOLOGY INC | SANA | COM | $2,637,619 | 755,736 | SH | None |
| 8X8 INC NEW | EGHT | COM | $1,694,354 | 990,850 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.